Journal Article

Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C→T Polymorphism at the Multidrug Resistance Gene 1

Sonia Rodríguez Nóvoa, Pablo Barreiro, Ana Rendón, Ana Barrios, Angélica Corral, Inmaculada Jiménez-Nacher, Juan González-Lahoz and Vincent Soriano

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 42, issue 2, pages 291-295
Published in print January 2006 | ISSN: 1058-4838
Published online January 2006 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/499056
Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C→T Polymorphism at the Multidrug Resistance Gene 1

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The 3435C→T polymorphism at the multidrug resistance gene 1 (MDR1) was examined in 74 patients with human immunodeficiency virus who initiated atazanavir therapy. The MDR1 genotype distribution at position 3435 was 28% CC, 45% CT, and 27% TT. Plasma levels of atazanavir were significantly higher in patients with genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations.

Journal Article.  2645 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.